University of British Columbia
Latest From University of British Columbia
Bayer will collaborate with start-up Hope Medicine to develop antibody therapies targeting the PRL receptor. WARF and Sanford Burnham Prebys partner on translational research.
Emerging Company Profile: A platform research company, AbCellera is not developing any drugs, but has seen triple-digit revenue growth each year since 2015 via a model of discovering next-generation therapeutic antibody candidates for partners.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced August and September.
Asterias obtains IP estate related to ischemic stroke from University of California. Plus Apeiron, Qualigen, Biovaxys and AbbVie turn to academic partners for early-stage cancer assets.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.